Navigation Links
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Date:12/5/2007

in research and development costs;

-- all other operating expenses flat with modest increases in Advertising

and Promotion, offset by a significant reduction in G&A expense; and

-- increase in effective tax rate to approximately 24%.

The GAAP guidance for 2008 includes the impact of restructuring and other charges related to the Productivity Transformation Initiative discussed below, but excludes proceeds from potential asset sales that have not yet been identified or quantified. Both the GAAP and non-GAAP guidance further assumes no significant acquisitions or divestitures and that the company and its product partner, sanofi-aventis, maintain exclusivity for the PLAVIX(R) patent through at least 2010.

Further, the non-GAAP 2008 guidance excludes charges related to the Productivity Transformation Initiative and other specified items that have not yet been identified and quantified, such as gains or losses from sale of businesses and product lines; from sale of equity investments and from discontinuations of operations; restructuring items that meet the requirements of SFAS 112 for severance and SFAS 146 for other exit costs; accelerated depreciation charges under SFAS 144 related to restructuring items described above; asset impairments; charges and recoveries relating to significant legal proceedings; upfront and milestone payments for in-licensing of products that have not achieved regulatory approval that are immediately expensed; copromotion or alliance charges and payments for in-process research and development which under GAAP are immediately expensed rather than amortized over the life of the agreement; income from upfront and milestone payments that is immediately recognized for out-licensing of products, including deferred income recognized upon termination; and significant tax events.

Details reconciling the 2007 and 2008 non-GAAP earnings per share guidance with GAAP amounts including specified items are provid
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... CitiusTech announced today that its BI-Clinical platform ... ACO quality measures that are part of the ACO ... BI-Clinical can now help ACO participants assess ... four domains - patient / caregiver experience, care coordination ...
... FLAGSTAFF, Ariz. More peer-reviewed scientific studies of ... and operations are needed to adequately assess their impact, ... literature review conducted by the U.S. Geological Survey and ... their literature review, the authors of the paper, USGS ...
... New findings by Virginie Stevens ( CNRS ), ... Naturelle ) and colleagues show that interactions between dispersal ... study was published as open access paper in the ... dispersal plays a key role in gene flow among ...
Cached Biology News:BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS 2Literature review on solar energy and wildlife impacts research 2Butterflies: 'Twice-punished' by habitat fragmentation and climate change 2
mIGSF4A Aff Pur PAb...
Human IL-19 MAb (Clone 152112)...
SRY (sex determining region Y)-box 10...
... Steel Staining tray 19 x 29 cm, ... and blot processing.Automated staining of Coomassie Blue ... acid analysis. Prepares blots for high sensitivity ... of protocol, solution, volume, and processing time.Proven ...
Biology Products: